Reduced dietary fat intake may decrease breast cancer recurrenceDecember 18, 2006Reducing dietary fat intake may decrease the chance of a breast cancer recurrence in women who have been treated for early-stage breast cancer, according to a randomized, phase III trial in the December 20 issue of the Journal of the National Cancer Institute. The relationship between dietary fat intake and breast cancer is unclear, both for primary breast cancer development and breast cancer recurrence. Rowan T. Chlebowski, M.D., Ph.D., of the Los Angeles Biomedical Research Institute at the Harbor-University of California, Los Angeles Medical Center in Torrance, Calif., and his colleagues set out to determine whether a low-fat diet could prolong relapse-free survival in women with early-stage breast cancer. Between February 1994 and January 2001, 2,437 women who had been treated for early-stage breast cancer were recruited from the Women's Intervention Nutrition Study (WINS). They were randomly assigned to a dietary intervention group (40%), or a control group (60%). The new study reports an analysis of all information collected as of October 31, 2003 with an average of 5 years of follow-up, when funding for the intervention ceased. The goal of the dietary intervention was to reduce dietary fat to 15% of total calories. Women in the intervention group attended eight biweekly, 1-hour counseling sessions to learn about a low-fat eating plan, and they kept written records of their daily fat gram intake. Dieticians contacted or met with the women every 3 months, and participants could attend optional monthly dietary group sessions. Women in the control group met with a dietician when they started the trial and were contacted by dieticians every 3 months. At the beginning of the study, both groups consumed similar amounts of calories from fat-56 to 57 grams of fat per day (about 30% of total calories). After 1 year, the women in the dietary intervention group were consuming an average of 33 g/day (20.3% of total calories) compared with 51 g/day (29.2% of total calories) in the control group. The difference between the two groups was maintained throughout the trial. Average body weight was similar before the trial started, but 5 years later, the women in the intervention group weighed an average of 6 pounds less than the women in the control group. Ninety-six of 975 women (9.8%) in the intervention group had some form of relapse, compared with 181 of 1462 women (12.4%) in the control group. The researchers calculate that 38 women would need to adopt such a dietary fat reduction plan to prevent one breast cancer recurrence. "Women in the dietary intervention group had a 24% lower risk of relapse than those in the control group," the authors write. Their data also suggest that women with hormone receptor-negative breast cancers may have had the most benefit from the dietary fat reduction, but those results weren't statistically significant and will require further confirmation. The authors plan to address these and other questions in ongoing follow-up studies of the women. They caution that the study relied on self-reports of dietary fat intake. Also, the reduction in body weight in the dietary intervention group may have had an effect on breast cancer recurrence, rather than dietary fat intake on its own. "The WINS results indicate that a lifestyle intervention designed to reduce dietary fat intake can be successfully implemented in women with early-stage, resected breast cancer receiving conventional cancer management in a multicenter clinical trial setting," the authors write. In an editorial, Anne C.M. Thiebaut, Victor Kipnis, and colleagues at the National Cancer Institute highlight the study's limitations and note the questions that it raises. They also point out the difficulty of conducting clinical trials of such drastic lifestyle changes. "WINS demonstrates that such trials can be successfully conducted"¦ The totality of this evidence will help us better understand the fat-breast cancer connection and ultimately provide more definitive public health recommendations," they write. Journal of the National Cancer Institute |
|||||||||||||||||||||
| Related Breast Cancer Current Events and Breast Cancer News Articles Menopause-cardiology consensus statement on cardiovascular disease and on HRT A menopause-cardiology consensus statement has called for direct action to prevent cardiovascular disease (CVD) in menopausal women. The statement also concludes that there is little evidence of increased CVD risk in taking HRT. Researchers Identify Role of Gene in Tumor Development, Growth and Progression Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. UCLA researchers create 'fly paper' to capture circulating cancer cells Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor. Fertility procedures need not delay breast cancer treatment for younger women A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. Coffee break: Compound brewing new research in colon, breast cancer A compound in coffee has been found to be estrogenic in studies by Texas AgriLife Research scientists. Drugs to treat anemia in cancer patients linked to thromboembolism Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. Discovery in worms by Queen's researchers points to more targeted cancer treatment Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment. FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated. Scientists uncover new key to the puzzle of hormone therapy and breast cancer The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. More Breast Cancer Current Events and Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||